Provided by Tiger Trade Technology Pte. Ltd.

Kodiak Sciences Inc.

23.04
+2.039.66%
Post-market: 23.430.3900+1.69%17:00 EST
Volume:747.66K
Turnover:16.98M
Market Cap:1.41B
PE:-5.59
High:23.46
Open:21.60
Low:21.24
Close:21.01
52wk High:31.18
52wk Low:1.92
Shares:61.05M
Float Shares:36.88M
Volume Ratio:0.99
T/O Rate:2.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1194
EPS(LYR):-3.3510
ROE:-207.92%
ROA:-47.21%
PB:59.37
PE(LYR):-6.88

Loading ...

Company Profile

Company Name:
Kodiak Sciences Inc.
Exchange:
NASDAQ
Establishment Date:
2009
Employees:
123
Office Location:
1200 Page Mill Road,Palo Alto,California,United States
Zip Code:
94304
Fax:
- -
Introduction:
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Directors

Name
Position
Victor Perlroth
Chief Executive Officer, President and Chairman of the Board
Bassil I. Dahiyat
Director
Felix J. Baker
Director
Richard S. Levy
Director
Robert A. Profusek
Director

Shareholders

Name
Position
Victor Perlroth
Chief Executive Officer, President and Chairman of the Board
Hong Liang
Senior Vice President, Discovery Medicine
John A. Borgeson
Senior Vice President and Chief Financial Officer
Jason Ehrlich
Chief Medical Officer and Chief Development Officer